MetaVia (MTVA) Competitors $0.64 0.00 (0.00%) As of 01:55 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsTrendsBuy This Stock MTVA vs. CUE, OVID, VRCA, ANL, HOWL, GNTA, ICCC, DRRX, CVM, and IMAShould you be buying MetaVia stock or one of its competitors? The main competitors of MetaVia include Cue Biopharma (CUE), Ovid Therapeutics (OVID), Verrica Pharmaceuticals (VRCA), Adlai Nortye (ANL), Werewolf Therapeutics (HOWL), Genenta Science (GNTA), ImmuCell (ICCC), DURECT (DRRX), CEL-SCI (CVM), and ImageneBio (IMA). These companies are all part of the "pharmaceutical products" industry. MetaVia vs. Its Competitors Cue Biopharma Ovid Therapeutics Verrica Pharmaceuticals Adlai Nortye Werewolf Therapeutics Genenta Science ImmuCell DURECT CEL-SCI ImageneBio MetaVia (NASDAQ:MTVA) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership. Is MTVA or CUE more profitable? MetaVia has a net margin of 0.00% compared to Cue Biopharma's net margin of -469.35%. MetaVia's return on equity of -212.00% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets MetaViaN/A -212.00% -107.21% Cue Biopharma -469.35%-230.13%-111.16% Do insiders and institutionals have more ownership in MTVA or CUE? 1.4% of MetaVia shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 0.8% of MetaVia shares are held by insiders. Comparatively, 10.8% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor MTVA or CUE? In the previous week, Cue Biopharma had 4 more articles in the media than MetaVia. MarketBeat recorded 8 mentions for Cue Biopharma and 4 mentions for MetaVia. MetaVia's average media sentiment score of 0.81 beat Cue Biopharma's score of 0.21 indicating that MetaVia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cue Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate MTVA or CUE? MetaVia currently has a consensus price target of $7.50, suggesting a potential upside of 1,071.88%. Cue Biopharma has a consensus price target of $4.00, suggesting a potential upside of 389.00%. Given MetaVia's higher probable upside, equities research analysts plainly believe MetaVia is more favorable than Cue Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, MTVA or CUE? MetaVia has higher earnings, but lower revenue than Cue Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetaViaN/AN/A-$27.59MN/AN/ACue Biopharma$9.29M6.77-$40.67M-$0.67-1.22 Which has more risk and volatility, MTVA or CUE? MetaVia has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. SummaryMetaVia beats Cue Biopharma on 7 of the 12 factors compared between the two stocks. Get MetaVia News Delivered to You Automatically Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTVA vs. The Competition Export to ExcelMetricMetaViaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.49M$3.14B$5.70B$9.81BDividend YieldN/A2.23%4.61%4.07%P/E RatioN/A20.7530.6225.55Price / SalesN/A367.71465.58116.50Price / CashN/A43.0338.2159.48Price / Book1.608.659.026.15Net Income-$27.59M-$54.65M$3.25B$264.98M7 Day Performance1.60%6.66%4.83%2.81%1 Month Performance-4.12%9.59%6.81%3.20%1 Year PerformanceN/A14.32%30.56%25.33% MetaVia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTVAMetaVia2.3024 of 5 stars$0.64flat$7.50+1,071.9%N/A$15.49MN/A0.008Gap DownCUECue Biopharma4.5119 of 5 stars$0.81+2.6%$4.00+393.6%+27.4%$61.06M$7.99M-1.2160Earnings ReportGap UpOVIDOvid Therapeutics4.4332 of 5 stars$0.86+56.9%$3.10+261.3%-16.8%$61.01M$548K-2.4560News CoverageEarnings ReportShort Interest ↑Gap UpHigh Trading VolumeVRCAVerrica Pharmaceuticals4.59 of 5 stars$6.59-3.4%$80.00+1,114.0%-80.3%$60.95M$7.18M-0.5540Earnings ReportShort Interest ↓High Trading VolumeANLAdlai Nortye1.3748 of 5 stars$1.65+6.5%$9.00+445.5%-46.7%$60.89MN/A0.00127Short Interest ↑Gap UpHOWLWerewolf Therapeutics3.7293 of 5 stars$1.35+12.5%$8.33+517.3%-33.7%$60.58M$1.88M-0.8140News CoverageEarnings ReportGNTAGenenta Science2.8091 of 5 stars$3.27-0.6%$25.00+664.5%-23.8%$59.81MN/A0.007Positive NewsGap UpICCCImmuCell0.5624 of 5 stars$6.53-1.8%N/A+90.9%$59.03M$26.49M-93.2770News CoverageEarnings ReportShort Interest ↓DRRXDURECT1.861 of 5 stars$1.90-0.5%N/A+42.9%$58.98M$2.03M-12.6780Earnings ReportShort Interest ↓CVMCEL-SCI1.2412 of 5 stars$8.35+9.4%N/A-76.4%$57.47MN/A-17.4043News CoverageShort Interest ↓IMAImageneBio3.1275 of 5 stars$14.20-3.2%$35.50+150.0%-26.2%$57.08M$9.16M-1.8570 Related Companies and Tools Related Companies CUE Alternatives OVID Alternatives VRCA Alternatives ANL Alternatives HOWL Alternatives GNTA Alternatives ICCC Alternatives DRRX Alternatives CVM Alternatives IMA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTVA) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access